ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that it has entered into agreements with Quintiles Commercial US, Inc. (Quintiles) and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL™ (bupivacaine liposome extended-release injectable suspension), should it be approved by the Food and Drug Administration (FDA) later this year. EXPAREL is the company's lead investigational product candidate for postsurgical pain management, which has been shown in Phase 3 clinical trials to be well-tolerated and to reduce postsurgical pain over an extended period of time compared with placebo.

Under the terms of the agreement with Quintiles, Quintiles will provide a U.S. sales force exclusively dedicated to EXPAREL that will consist of approximately 70 people and will support sales efforts through December 31, 2012, or beyond if extended in accordance with the terms of the agreement. Under the terms of the agreement with ICS, ICS will serve as the exclusive third party logistics provider to Pacira to support the U.S. commercialization of EXPAREL for the next three years. Both agreements may be terminated by Pacira at will in accordance with the terms of the two agreements.

"We have made significant progress executing our dynamic launch strategy for EXPAREL that leverages the growing body of positive clinical data and our supportive health outcome studies in anticipation of potential FDA approval in late October," said David Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. "Under the terms of our agreement with Quintiles, we will have direct input into the selection of the newly developed, Pacira-specific sales force, which should allow us to create a dynamic, engaged team and leverage the expertise and functionality of the Quintiles organization.  We believe these data, the valuable relationships we are building and strengthening within key clinical communities, and these new agreements will position us to aggressively launch EXPAREL if it is approved later this year.  We remain excited about the opportunity to commercialize EXPAREL as we believe it can provide unique utility and health outcome benefits to physicians, patients and hospitals."

SOURCE Pacira Pharmaceuticals, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quintiles. (2011, September 06). ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL. News-Medical. Retrieved on January 26, 2021 from https://www.news-medical.net/news/20110906/ICS-Quintiles-enter-agreement-with-Pacira-to-support-launch-of-EXPAREL.aspx.

  • MLA

    Quintiles. "ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL". News-Medical. 26 January 2021. <https://www.news-medical.net/news/20110906/ICS-Quintiles-enter-agreement-with-Pacira-to-support-launch-of-EXPAREL.aspx>.

  • Chicago

    Quintiles. "ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL". News-Medical. https://www.news-medical.net/news/20110906/ICS-Quintiles-enter-agreement-with-Pacira-to-support-launch-of-EXPAREL.aspx. (accessed January 26, 2021).

  • Harvard

    Quintiles. 2011. ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL. News-Medical, viewed 26 January 2021, https://www.news-medical.net/news/20110906/ICS-Quintiles-enter-agreement-with-Pacira-to-support-launch-of-EXPAREL.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Quintiles' growth in service revenues increases 7.7% in Q4 2013